ERADICATE: A Phase Ib/II Study of Elacestrant Plus Trastuzumab Deruxtecan in Patients With CDK4/6 Inhibitor and Endocrine-resistant HR+/HER2-low or HER2-ultralow Metastatic Breast Cancer
NCT07198724 · RECRUITING · Phase 2
We track 1 ClinicalTrials.gov studies led by Sarah Sammons Md. The portfolio skews toward Phase 2 (1 trials).
1 clinical trials sponsored by Sarah Sammons Md.
| Phase | Trials | Distribution |
|---|---|---|
| Phase 2 | 1 | 100% |
Sarah Sammons Md currently sponsors 1 clinical trials tracked on ReadTheTrial. These span Phase 2.
Sarah Sammons Md conducts research across multiple therapeutic areas. Browse the trial listings for details.
Yes, Sarah Sammons Md currently has 1 trial that are actively recruiting participants. Check individual trial pages for eligibility criteria and locations.